Semax

Semax was developed through Russian peptide research programs examining short fragments of adrenocorticotropic hormone, or ACTH. Researchers were interested in whether neurological activity associated with ACTH fragments could be separated from the adrenal-stimulating effects of the full 39-amino-acid hormone.¹ The resulting seven-amino-acid peptide combines the ACTH(4-7) sequence, Met-Glu-His-Phe, with Pro-Gly-Pro. It is often described as an ACTH(4-10) analog, although it is not the same sequence: Semax replaces the Arg-Trp-Gly portion of natural ACTH(4-10) with Pro-Gly-Pro. This modification was designed to improve resistance to enzymatic degradation.¹ ² Research subsequently expanded into cognition, cerebral ischemia, neurotrophin signaling and neuroinflammation. Human studies have examined neurological rehabilitation and cognitive settings, but the clinical literature remains smaller and less independently replicated than the preclinical literature. Semax is historically significant as an attempt to create a stabilized, non-corticotropic ACTH-derived regulatory peptide. It is not equivalent to ACTH, and it is not FDA-approved for therapeutic use in the United States.

Semax does not have one conclusively identified primary receptor. Experimental research instead supports time-dependent and brain-region-specific effects across several neurological pathways. The most studied pathway involves BDNF and its receptor TrkB. Rodent studies have reported changes in BDNF expression, BDNF protein and TrkB expression or activation after Semax exposure.³ These findings suggest modulation of the BDNF signaling environment; they do not show that Semax binds directly to TrkB. Specific binding has been reported in rat basal-forebrain tissue, but the responsible binding protein was not identified.⁴ Other animal studies have found region-specific changes in dopamine and serotonin systems, along with changes in NGF, NT-3 and injury-responsive gene expression.⁵–⁸ In cell and cerebral-ischemia models, researchers have also examined calcium regulation, mitochondrial membrane stability, oxidative signaling and inflammatory gene networks.⁹–¹¹ These observations should not be collapsed into one proven linear cascade. Semax is therefore best described as a multi-pathway regulatory peptide. Most detailed mechanism evidence remains preclinical, and a complete human mechanism has not been established.